PanCytoVir (probenecid) / TrippBio - LARVOL DELTA

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: TrippBio, Inc. | Not yet recruiting ➔ Completed | Trial primary completion date: Jul 2024 ➔ Sep 2024

Trial completion • Trial primary completion date

An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: TrippBio, Inc. | Not yet recruiting ➔ Completed | Trial primary completion date: Jul 2024 ➔ Sep 2024

Trial completion • Trial primary completion date

An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: TrippBio, Inc. | Trial completion date: Feb 2024 ➔ Oct 2024 | Initiation date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Feb 2024 ➔ Jul 2024

Trial completion date • Trial initiation date • Trial primary completion date

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: TrippBio, Inc. | Trial completion date: Feb 2024 ➔ Oct 2024 | Initiation date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Feb 2024 ➔ Jul 2024

Trial completion date • Trial initiation date • Trial primary completion date

An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: TrippBio, Inc.

Trial completion date • Trial initiation date • Trial primary completion date

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: TrippBio, Inc.

Trial completion date • Trial initiation date • Trial primary completion date

An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: TrippBio, Inc.

New P1 trial

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: TrippBio, Inc.

New P1 trial

TrippBio Reports Positive Results from Investigator-Initiated Clinical Trial of TD213 for the Treatment of Mild to Moderate COVID-19 Infections (PRNewswire) - P=NA, N=NA; "Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were given TD213 twice daily for 14 days and will be followed through day 28. After 14 days, 90% of enrolled patients receiving TD213 had cleared the virus....'I was very pleased to see that 20% of the patients cleared by day five, and 40% by day ten, as well as the 14-day clearance data'....An initial review of laboratory tests showed that a critical marker of inflammation, high-sensitive C-reactive protein (hsCRP), improved after four days of treatment in 60% of patients and 90% of patients after 14 days of treatment."

Biomarker • Clinical data • Infectious Disease • Novel Coronavirus Disease

TrippBio Announces the Completion of Enrollment in a Proof of Concept Clinical Trial Evaluating the Efficacy of TD213 in Treating Patients with Confirmed COVID-19 Infections (PRNewswire) - "Dr. Moti N. Ramgopal of Midway Immunology and Research Center launched the investigator-initiated study (IIS) to assess the efficacy of TD213 in treating patients with confirmed mild - moderate COVD-19 infections. Dr. Ramgopal announced the final patient was enrolled in this proof of concept (POC) study....'So far, the drug is well tolerated, and we are looking forward to analyzing the data on TD213 impact on viral clearance and markers of inflammation'....'We plan to take the data from this study and the University of Georgia to the FDA in support of the rapid development of a pivotal Ph II/III study...and if applicable apply for an Emergency Use Authorization.'"

Enrollment closed • Infectious Disease • Novel Coronavirus Disease